The Keytruda news has great implication on Kevetrin. P53 is a gene and mutant p53 contains mutations in the nucleic acid sequence. So I think mutant p53 should qualify as a genetic marker. Kevetrin has the ability to degrade mutant p53 and hopefully the K-OC trial will confirm its MOA.

Quote:

---

Merck & Co's immunotherapy Keytruda on Tuesday became the first cancer drug ever approved by the U.S. Food and Drug Administration based on a patients' specific genetic traits, regardless of where in the body the disease originated.

---